Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 5906.074 | 0.4068 | -0.5049 | 0.6442 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 5906.074 | 0.4068 | -0.5049 | 0.6442 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 5906.074 | 0.2556 | -0.7594 | 0.6442 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 5906.074 | 0.2556 | -0.7594 | 0.6442 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 5906.074 | 0.1534 | -0.8911 | 0.6442 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 5906.074 | 0.1534 | -0.8911 | 0.6442 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 167 | uM | 5906.074 | 0.1438 | -0.9015 | 0.6442 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 167 | uM | 5906.074 | 0.1438 | -0.9015 | 0.6442 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14825.203 | 1.0003 | 1.0009 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14825.203 | 1.0003 | 1.0009 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14825.203 | 0.9922 | 0.9721 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14825.203 | 0.9922 | 0.9721 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14825.203 | 0.9825 | 0.9379 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14825.203 | 0.9825 | 0.9379 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14825.203 | 0.5443 | -0.3246 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14825.203 | 0.5443 | -0.3246 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14825.203 | 0.4917 | -0.4364 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14825.203 | 0.4917 | -0.4364 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14825.203 | 0.3744 | -0.6535 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14825.203 | 0.3744 | -0.6535 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14825.203 | 0.2494 | -0.8321 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14825.203 | 0.2494 | -0.8321 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14825.203 | 0.2335 | -0.8508 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14825.203 | 0.2335 | -0.8508 | 0.5604 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14825.203 | 0.2015 | -0.8853 | 0.5604 |